Marker Therapeutics, Inc.
MRKR
$1.27
$0.086.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 43.16% | 146.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 43.16% | 146.69% | |||
| Cost of Revenue | -- | 33.22% | |||
| Gross Profit | 137.18% | -19.01% | |||
| SG&A Expenses | 8.32% | -30.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -34.21% | 13.71% | |||
| Operating Income | 49.85% | -2.54% | |||
| Income Before Tax | 50.23% | 9.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 50.23% | 9.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 50.23% | 9.68% | |||
| EBIT | 49.85% | -2.54% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 58.53% | 28.13% | |||
| Normalized Basic EPS | 58.57% | 19.98% | |||
| EPS Diluted | 58.62% | 27.55% | |||
| Normalized Diluted EPS | 58.57% | 19.98% | |||
| Average Basic Shares Outstanding | 20.07% | 25.67% | |||
| Average Diluted Shares Outstanding | 20.07% | 25.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||